Просмотр новости
Найдите то, что Вас интересует
Спутники
РН
SpaceX
Роскосмос
NASA
СпутникиРНSpaceXРоскосмосNASAGLP-1 receptor agonist therapy was associated with lower all-cause mortality among people with hidradenitis suppurativa — a benefit that lasted up to 2 years, according to a study published in JAMA Dermatology.These findings were consistent even among patients without diabetes who had HS, according to Beata Jastrząb-Miśkiewicz, MD, PhD, a dermatologist, venereologist and lead investigator of the study.“It suggests that the association between GLP-1 receptor agonists and improved HS outcomes may not be explained only by better glycemic control,” Jastrząb-Miśkiewicz told Healio. “It raises
| # | Наименование новости | Тональность | Информативность | Дата публикации |
|---|---|---|---|---|
| 1 | Do GLP-1s belong in dermatology? Evidence suggests a growing role | 0 | 11.72 | 12-08-2026 |
| 2 | GLP-1s may improve outcomes in patients with PAD, diabetes | 5 | 7 | 08-07-2026 |
| 3 | GLP-1s for diabetes may increase risk for psoriatic disease | 0 | 8.45 | 28-07-2026 |
| 4 | GLP-1 Medications May Improve Health in People With PAD and Diabetes | 0 | 9.88 | 18-08-2026 |
| 5 | Most websites prescribe GLP-1s without clinician visit | 0 | 7 | 09-07-2026 |
| 6 | Beyond the Jab: The Surprising New Frontiers of GLP-1 Therapy | 0 | 14.13 | 24-07-2026 |
| 7 | Combination GLP-1 and SGLT2 therapy may lower heart risk | 0 | 5 | 25-06-2026 |
| 8 | Decoding the evidence on peptides, from topicals to longevity | 2 | 6 | 09-07-2026 |
| 9 | Doctors' fears over long-term Ozempic use: DR SHEILA sounds the alarm over GLP-1 weight-loss drugs for young patients | -2 | 6 | 27-06-2026 |
| 10 | Eli Lilly's Mounjaro shows heart health benefits in head-to-head trial with older diabetes drug Trulicity | 7 | 8 | 31-07-2025 |